

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MT	Malta	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

POLYMORPHISM II. LINKAGE OF ASTHMA TO A LOCUS ON CHROMOSOME 4

This invention is concerned with methods for the diagnosis of asthma and with materials and methods relating thereto.

5 Asthma is a disease which is becoming more prevalent and is the most common disease of childhood (1). Most asthma in children and young adults is initiated by IgE mediated allergy (atopy) to inhaled allergens such as house dust mite and cat dander. However, not all asthmatics are atopic, and most atopic individuals do not have asthma, so that factors in
10 addition to atopy are necessary to induce the disease (2,3). Asthma is strongly familial, and is due to the interaction between genetic and environmental factors. The genetic factors are thought to be variants of normal genes ("polymorphisms") which alter their function to predispose to asthma.

15 Asthma may be identified by recurrent wheeze and intermittent air flow limitation. An asthmatic tendency may be quantified by the measurement of bronchial hyper-responsiveness in which an individual's dose-response curve to a broncho-constrictor such as histamine or methacholine is constructed. The curve is commonly summarised by the dose
20 which results in a 20% fall in air flow (PD20) or the slope of the curve between the initial air flow measurement and the last dose given (slope). Asthma is accompanied by blood eosinophilia, and eosinophils are prominent in asthmatic airways.

25 In the atopic response, IgE is produced by B-cells in response to allergen stimulation. These antibodies coat mast cells by binding to the high affinity receptor for IgE (FcεRI). When a multivalent allergen binds to an IgE-coated mast cell, the cross-linking of adjacent IgEs by allergen initiates a series of cellular events leading to the destabilisation of the cell membrane

and release of inflammatory mediators. This results in mucosal inflammation, wheezing, coughing, sneezing and nasal blockage.

Atopy can be diagnosed by (i) a positive skin prick test in response to a common allergen; (ii) detecting the presence of specific serum
5 IgE for allergen; or (iii) by detecting elevation of total serum IgE.

Genetic factors underlying a disease may be identified through localisation to particular chromosomal regions by genetic linkage. Genetic linkage is established by the study of families. It relies on matching the inheritance of disease with genetic polymorphisms of known localisation
10 (known as "genetic markers"). In a complex disease such as asthma, genetic linkage will typically localise genes to within 10 - 20 Megabases (Mb) of DNA. A region of this size may contain 350 - 700 genes, and will be too large to permit immediate identification of the disease-causing gene.

Closer localisation of disease-causing genes may be
15 accomplished by the detection of associations between particular alleles and the disease phenotype. Over short segments of DNA, distinctive alleles of the individual polymorphisms will show non-random association with alleles of neighbouring polymorphisms. This phenomenon, known as "linkage disequilibrium" occurs over 50-500 Kilobases (Kb) of DNA. Linkage
20 disequilibrium may be detected by the study of individuals as well as by the study of families.

Disease-causing alleles will be in linkage disequilibrium with non-functional polymorphisms from the same chromosomal segment. It is therefore possible to detect allelic association with disease from particular
25 chromosomal segments, without identifying the exact polymorphism and gene underlying the disease state.

The detection of allelic association may therefore give information as to disease susceptibility in a particular individual. Furthermore,

allelic association is indicative of a disease-causing gene being present within 500 Kb of DNA in either direction from the allele (i.e. 1 Mb in total). Such a region may contain only 30 genes, within which the identification of the disease-causing gene is possible.

5 The presence of linkage disequilibrium also means that other polymorphisms may be anticipated to associate with disease, and that these additional polymorphisms will also be diagnostic of disease susceptibility in particular individuals.

Genetic associations with atopy have been demonstrated.
10 WO 95/05481 discloses that variants of the gene encoding the β -subunit of the high-affinity receptor for IgE (Fc ϵ RI β) are associated with atopy. It teaches a method for diagnosing atopy which is based upon the demonstration of the presence or absence of one of two variants in a specific portion of the DNA sequence of the gene encoding Fc ϵ RI β , located near the commencement of exon 6 of the Fc ϵ RI β gene on chromosome 11. A further
15 variant has also been found in which the unusual variant sequence is in the coding sequence for the C-terminal cytoplasmic tail of Fc ϵ RI β (4).

Tumour Necrosis Factor (TNF) is a pro-inflammatory cytokine that is found in increased concentration in asthmatic airways (5). We have
20 previously shown that polymorphisms within the TNF gene are associated with an increased risk of asthma (6).

The Known polymorphisms do not account for all of the genetic factors which predispose to asthma. In particular, asthma is not necessarily an atopic disease. Identification of further genetic polymorphisms linked to
25 asthma will allow the identification of children at risk of asthma before the disease has developed (for example immediately after birth), with the potential for prevention of disease. The presence of particular polymorphisms may predict the clinical course of disease (e.g. severe as opposed to mild) or the

response to particular treatments. This diagnostic information will be of use to the health care, pharmaceutical and insurance industries.

We have previously established linkage of bronchial hyper-responsiveness to chromosome 4 (8). However, this finding is of no use in
5 diagnosis.

It has now been discovered that a genetic polymorphism known as D4S3032*5 on chromosome 4 and a nearby polymorphism known as D4S2921*13 are associated with asthmatic traits. Specifically, D4S3032*5 is associated with bronchial hyper-responsiveness and D4S2921*13 is
10 associated with peripheral eosinophilia, both of these being traits which underlie asthma. The two polymorphisms can therefore be used as diagnostic tools.

The invention therefore provides a method for diagnosing an individual as being asthmatic, or as having a predisposition to asthma, which
15 method comprises demonstrating in the individual the presence or absence of one or more alleles which are associated with asthma, wherein the one or more alleles are situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921.

20 The 1Mb region of chromosome 4 referred to flanks the D4S3032 and D4S2921 loci. Thus, the specific allele D4S3032*5, or D4S2921*13, or other unusual polymorphisms in the region which are associated with asthma, may be the subject of identification in the method according to the invention. Equally two or more such alleles may be the
25 subject of identification, including in particular the combination of D4S3032*5 and D4S2921*13.

Current diagnostic methods involving detection at the nucleic acid level normally comprise the steps of:

- (i) obtaining a suitable tissue sample from the individual;
- (ii) preparing from the tissue sample a nucleic acid sample;
- (iii) analysing the nucleic acid sample for the presence or absence of the relevant nucleic acid sequence, such as a specific allele.

5

Preferably, an amplification step is performed prior to the analysis, such that the locus at which the allele is situated is amplified. A preferred amplification technique is the PCR, although any suitable method of nucleic acid amplification may be employed.

10

In further aspects, the invention provides a pair of oligonucleotide primers for amplification of an allele which is associated with asthma, which allele is situated at a locus in a region of chromosome 4 of up to 1 megabase in length, which region contains the locus D4S3032 and/or D4S2921; and an assay kit comprising the pair of oligonucleotide primers.

15

The specific allele for identification may take the form of microsatellite repeats, which are nucleotide sequences containing short, repeated nucleotide motifs, usually a dinucleotide or a trinucleotide motif. A pair of primers which hybridize under suitably stringent conditions, to sequences at a position on either side of the microsatellite repeats, may be used to amplify the microsatellite repeats by PCR. Differences in the number of repeats are recognised by size differences in the PCR products. An allele which has a specified number of repeats and therefore a known size can thus be identified. D4S3032*5 and D4S2921*13 are examples of such alleles.

20

The primers employed in the method comprise nucleic acid sequences which are complementary to, or substantially complementary to unique sequences either side of the microsatellite repeats, such that only the relevant polymorphic region of the genome is amplified. The conditions under which the amplification is performed are gauged such that specific

25

hybridization of the primers to the flanking sequences occurs and non-specific hybridization is avoided. The hybridization conditions are suitably stringent for that purpose. Standard techniques can be used to identify an appropriate set of reaction conditions.

- 5 Typically, the PCR products are detected by means of a detectable label attached to one of the PCR primers. Alternatively another form of labeling may be used such as a labeled sequence specific probe which hybridizes to the amplified sequences. The label may be a fluorescent or other label. The PCR products are subjected to size determination,
10 typically involving size-separation for example by gel electrophoresis, and the presence or absence of the allele of interest is determined.

- It will be evident that the invention is not limited with regard to the manner in which the presence or absence of the allele of interest is determined. The labeling, detection, separation or any other aspect of the
15 method as described here may be replaced by other suitable known techniques and reagents.

- The allele for identification may be an allele other than D4S3032*5 or D4S2921*13 which is in linkage disequilibrium with D4S3032*5 or D4S2921*13 and is associated with asthma. This includes alleles of both
20 functional and non-functional polymorphisms. Functional polymorphisms include polymorphisms within genes, usually within coding sequences of genes. Non-functional polymorphisms are polymorphisms which do not themselves cause the disease.

- This invention will now be further described in the Examples
25 section which follows. The Examples are intended to be illustrative and do not limit the scope of the invention in any way.

EXAMPLES

Description of Laboratory Testing

Subjects

Two panels of subjects have been studied.

5 Panel A consisted of 80 nuclear families sub-selected from an Australian population sample of 230 families (8). The panel contained a total of 203 offspring forming 172 sib-pairs. 12% of the children were asthmatic.

Panel C consisted of 87 nuclear families recruited through a child attending an asthma clinic in the Oxford region. The families contained
10 216 offspring (148 sibling pairs), of whom 44% were asthmatic.

Phenotyping

Bronchial responsiveness to methacholine was measured as previously described (8): the maximum dose administered was 12 μ mol. The
15 slope of the dose-response curve was calculated as (pre-dose forced expiratory volume in one second (FEV1) - last FEV1) \div the cumulative dose of methacholine). A constant of 0.01 was added to each measurement, to allow loge transformation when Slope was \leq 0. Eosinophils in peripheral blood were Coulter-counted and the values \log_e transformed before analysis.

20

Genotyping

The microsatellite markers D4S3032 and D4S2921 were typed by semi-automated fluorescent methods, as described previously (8). These
25 markers are in close proximity at the telomeric region of the long arm of chromosome 4.

The polymerase chain reaction primer sequences for the markers were as follows:

D4S3032 5' TGA AAT TCT ATT GAC CAA TGA TGT G (SEQ ID NO: 1)

UD4S3032 5' TAG CAC CTG GAT TTA CCA TGA C (SEQ ID NO: 2)

D4S2921 5' TCC TTC AGG AAC TGG TG (SEQ ID NO: 3)

UD4S2921 5' TTA AAA ATC TAC AGA CAA GGG C (SEQ ID NO: 4)

5 The polymerase chain reaction conditions were as follows: The reaction volumes were 10 μ l, containing 50ng of genomic DNA, 200mM dNTPs, 1 x NH4+ buffer, 50ng oligonucleotide primers (forward labelled fluorescently), 0.5 to 3.0mM MgCl₂ and 0.2U Taq polymerase. Cycling conditions were 1 min at 95°C, 1 min at 55°C and 45s at 72°C; 28 cycles were
10 used. PCRs were performed on an Hybaid Omnigene thermal cycler.

Electrophoresis and allele scoring were as follows:

PCR products were mixed with a size standard (GS350 TAM) in loading buffer (80% (v/v) formamide, 20% (v/v) 50mM EDTA, 0.1% (w/v) blue dextran). Samples were denatured at 95°C for 4 min immediately prior to loading onto a
15 6% polyacrylamide gel and were electrophoresed at 800v for 6h on an Applied Biosystems (ABI) 313 DNA sequencer. Allele sizes were assigned using the ABI GENESCAN and ABI GENOTYPER software.

Association Analysis

20 Association was tested against the phenotype of bronchial hyper-responsiveness and peripheral blood eosinophil counts by the ASSOC routine of the SAGE (ver2.2) computer program.

Results

25

Association with D4S3032 allele 5 and D4S2921 allele 13

Each of the markers was then tested for association with the asthma phenotype. Association was seen in panel A for allele 5 of D4S3032

(D4S3032*5) and bronchial hyper-responsiveness. This allele is 145 base pairs in size, using the primers described above. Association between allele 13 of D4S2921 (D4S2921*13) and eosinophil counts were seen in both panels. This allele is 162 base pairs in size, using the primers described above. (Other suitable primers can be designed and their amplification product size determined for D4S3032*5 or D4S2921*13, using known sequence information (9).) The results of testing were as follows:

Trait	Marker	Allele	Panel A		Panel C		Combined	
			χ^2	p	χ^2	p	χ^2	p
Slope	d4s3032	5	13.56	0.0002	-	-	-	-
Eosinophils	d4s2921	13	5.00	0.03	11.17	0.0008	17.61	0.0000

The recombination fraction between D4S3032 and D4S2921 was 3%, indicating in this telomeric region that the distance between the markers is of the order of 0.5 to 1 megabase.

The results indicate that D4S3032*5 and D4S2921*13 show strong association with intermediate phenotypes underlying asthma in two diverse panels of subjects. It may therefore be inferred that a gene influencing asthma is present within 500 kilobases in either direction of D4S3032 and D4S2921.

REFERENCES

- Strachan, D.P., Anderson, H.R., Limb, E.S., O'Neill, A. and Wells, N. (1994). A national survey of asthma prevalence, severity, and treatment in Great Britain. *Arch. Dis. Child.*, **70**, 174-178.

2. Fraser, R.S., Paré, J.A.P., Fraser, R.G. and Paré, P.D., eds. (1994) Synopsis of Diseases of the Chest. WB Saunders Company, Philadelphia: 635-53.
3. Djukanovic, R., Roche, W.R., Wilson, J.W., Beasley, C.R., Twentyman, O.P., Howarth, R.H. and Holgate S.T. (1990) Mucosal inflammation in
5 asthma. *Am. Rev. Respir. Dis.*, **142**, 434-457.
4. Hill, M.R. and Cookson, W.O.C.M. (1996). A new variant of the β subunit of the high-affinity receptor for Immunoglobulin E (Fc ϵ RI- β E237G): Associations of measures of atopy and bronchial hyper-responsiveness. *Hu.*
10 *Mol. Gen.* **5**, 959-962.
5. Broide, D.H., Lotz, M., Cuomo, A.J., Coburn, D.A., Federman, E.C. and Wasserman, S.I. (1992) Cytokines in symptomatic asthma airways. *J. Allergy Clin. Immunol.* **89**, 958-967.
6. Moffatt M.P., Cookson WOCM. Tumour Necrosis Factor Haplotypes.
15 and Asthma. *Hum Molec Genet* 1997; **6**: 551-554.
7. Bailly S, di Giovine FS, Blakemore A.I.F, Duff G.W. Genetic polymorphism of human interleukin-1 α . *Eur J Immunol* 1993; **23**: 1240-1245.
8. Daniels S.E, Bhattacharyya S, James A, Leaves N.I, Young A, Hill M.R, Faux J.A, Ryan G.F, le Souef P.N, Lathrop G.M, Musk A.W, Cookson
20 W.O.C.M. A genome-wide search for quantitative trait loci underlying asthma. *Nature* 1996; **383**: 247-250.
9. Dib S. et al. A comprehensive map of the human genome based on 5264 microsatellites. *Nature* 1996; **380**: 152-154.

b1 7